Last reviewed · How we verify
NCT06872905
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
trial testing GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX) in Aortoiliac Occlusive Disease in 158 participants. Currently enrolling.
16 August 2027
Quick facts
| Lead sponsor | W.L.Gore & Associates |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 158 |
| Start date | 30 May 2025 |
| Primary completion | 16 August 2027 |
| Estimated completion | 16 August 2027 |
| Sites | 19 locations across Italy, Netherlands, United Kingdom, United States, Spain |
Drugs / interventions tested
- GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)
Conditions studied
- Aortoiliac Occlusive Disease — all drugs for Aortoiliac Occlusive Disease →
Sponsor
W.L.Gore & Associates — full company profile →
Who can join
Adults 18 to 100, any sex, with Aortoiliac Occlusive Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will assess the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis ("VBX Device" or also referred to as "VBX Stent Graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstruction of the aortic bifurcation (CERAB) to treat Aortoiliac Occlusive Disease (AIOD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06872905
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortoiliac Occlusive Disease
Currently open trials in the same condition.
- NCT06253312 — Treatment of TASC C and D Aortoiliac Lesions · recruiting
- NCT07048925 — Iliac Stent-Grafts in TASC C-D Lesions · active not recruiting
- NCT05972018 — Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters · Phase 4 · recruiting
- NCT05811364 — The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Me · NA · recruiting
Other W.L.Gore & Associates trials
Trials by the same sponsor.
- NCT07147569 — TAMBE Japan Post-Marketing Surveillance · recruiting
- NCT06827990 — GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections · NA · recruiting
- NCT06578741 — GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study · NA · enrolling by invitation
- NCT06174376 — Clinical Outcomes of the Gore Synthetic Cornea Device · NA · recruiting
- NCT06218875 — Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06872905 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by W.L.Gore & Associates
- Last refreshed: 30 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06872905.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing